Physician profile
Christopher Scott Randolph
NPI 1669455606
$4,152.35
in general payments reported to CMS, 2019-2025
20 companies · $1,021 in 2025
The $1,021 reported for 2025 was more than what 81% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $203 · 2020: $34.71 · 2021: $381 · 2022: $743 · 2023: $1,128 · 2024: $641 · 2025: $1,021.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,711 · Education: $79.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,711.06 |
| Education | $79.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,021.40 | 2021-2025 | |
| Teva Pharmaceuticals USA, INC. | $450.86 | 2022-2025 | Austedo Xr, Austedo Xr, Austedo |
| Otsuka America Pharmaceutical, INC. | $389.16 | 2020-2025 | Abilify Asimtufii, Abilify Maintena, Rexulti |
| Alkermes, INC. | $356.89 | 2020-2025 | Aristada, Lybalvi |
| Neurocrine Biosciences, INC. | $333.92 | 2023-2025 | Ingrezza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $280.47 | 2023-2025 | Caplyta |
| Takeda Pharmaceuticals U.S.A., INC. | $253.76 | 2019-2025 | Trintellix |
| Supernus Pharmaceuticals, INC. | $245.31 | 2022-2025 | Qelbree, Qelbree |
| Lundbeck LLC | $193.90 | 2019-2024 | Rexulti |
| Corium, LLC | $121.13 | 2022-2025 | Azstarys |
| Noven Therapeutics, LLC | $107.97 | 2023 | Xelstrym, Secuado |
| Eisai INC. | $85.22 | 2021-2022 | |
| Axsome Therapeutics, INC. | $66.02 | 2024-2025 | Auvelity |
| Collegium Pharmaceutical, INC. | $53.18 | 2025 | Jornay Pm |
| Vertical Pharmaceuticals, LLC | $50.14 | 2024-2025 | Relexxii |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $49.37 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $30.13 | 2023 | Invega Sustenna, Invega Trinza |
| Noven Pharmaceuticals, INC. | $21.33 | 2024 | Xelstrym |
| Ironshore Pharmaceuticals INC. | $21.31 | 2024 | |
| E.R. Squibb & Sons, L.L.C. | $20.88 | 2025 | Cobenfy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Randolph listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.